Compumedics Limited · ASX:CMP
Compumedics — Shareholder Meeting (October 2002)
23 slides from Compumedics's shareholder meeting presentation, Oct 24, 2002
Slide 1: Compumedics Limited Annual General Meeting
Compumedics Limited Annual General Meeting 24 October, 2002 1
Slide 2: Agenda
Agenda l Meeting Opens l Chairman’s Address l Ordinary Business l Meeting Closes 2
Slide 3: Chairman's Address
Chairman’s Address
Slide 4: Outline
Outline 1. Full Year Results 2002 2. Compumedics Business Moving Forward 4
Slide 5: Results Full Year - Key Points
Results Full Year - Key Points - Strong growth in Asia – up 71% Operating Revenue - USA and Europe impacted by up 19% from PCP distribution – now resolved - Australia is steady - Specific adjustments are $1.1m PAT of $(1.9m) after tax compared to profit - Remaining after tax loss $0.8m of $2.0m PCP
Slide 6: Historical Sales Graph
Historical Sales Graph 18 16 14 12 10 8 6 4 2 0 A$m '94 '95 '96 '97 '98 '99 '00 '01 '02 Export Sales Domestic Sales Other Income 6
Slide 7: Strong growth in Asia, US continues to expand
Strong growth in Asia, US continues to expand Full Year ‘01 Full Year ‘02 Europe Australia Australia 18% 21% Europe 17% 11% Asia Asia 25% 18% USA USA 43% 47% 7
Slide 8: Business Achievements - 2002
Business Achievements - 2002 • Neuroscan acquisition, successful restructure and integration • Direct access to USA sleep market (largest device market in the world) • Strategic links with Dräger for European market access • Direct support office established in Hamburg to reinforce European market p
Slide 9: The global market continues to grow
The global market continues to grow US$m Combined Sleep / EEG / CHF Holter Diagnostics and Monitoring Market - Global* 3500 2918 3000 2567 2500 2258 1991 2000 1753 1538 1348 1500 1039 1183 822 918 1000 500 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Global market breakdown for 2002: • S
Slide 10: Market Position
Market Position l Market Share – 70% domestic sleep market share – 45% domestic EEG market share – 8% USA sleep market share l Competition update – Main competitors: Respironics, Tyco (Mallinckrodt) Sensormedics, Medcare, Biologic 10
Slide 11: Performance relative to PCP
Performance relative to PCP $Am 12 mths to 12 mths to Variance June 30 June 30 2001 2002 Revenues - Operating 16,639 19,747 18.7% - Other 1,678 463 N/A Total Revenue 18,317 20,210 10.3% EBITDA 4,223 (893) N/A EBIT 3,041 (2,387) N/A Profit after Tax 1,971 (1,898) N/A Gross Margin 62.9% 63.6% 0.07% EB
Slide 12: Balance Sheet relative to PCP
Balance Sheet relative to PCP June 2001 June 2002 A$’000 A$’000 Current Assets Cash 11,447 8,533 Receivables 8,993 7,983 Inventory 4,965 8,520 Other 696 187 Total 26,100 25,223 Non current assets Receivables 324 106 Property, Plant and Equipment 822 958 Intangibles 11,951 17,338 Other - - Total asse
Slide 13: Financial Performance
Financial Performance l Costs – Costs initiatives implemented – Direct selling resources in place a large part of current year cost increase l Margins stable – June 00 - 61%, June 01 - 63%, June 02 – 63%* – The consolidation of manufacturing for both business will enhance margins as we move forward
Slide 14: Moving Forward
Moving Forward - Expanded direct access to the US Expansion of core hospital market sleep diagnostic - New relationship with Dräger business Medical in Europe - Japanese and rest of Asia market growth Develop - Expansion of Neuroscan EEG businesses in market in ROW associated areas - Expansion of Cl
Slide 15: Core Products
Core Products E-Series l New generation laboratory based diagnostic product for both full polysomnography (PSG) “sleep” studies and or separate EEG studies. Siesta l World leading portable diagnostic device with wireless capability for both sleep and general patient monitoring. Somté l Combined Slee
Slide 16: Core Products
Core Products SynAmps l The most sophisticated neurological amplifier available on the market. These amplifiers can be combined to obtain up to 256 channels of physiological data. Scan l Provides for the acquisition of the EEG and Evoked Potential data including a rich set of clinically popular and
Slide 17: Product and Technology Development
Product and Technology Development l Last 12 months – CE Mark Somté – SPAP patent approvals – Safiro – EEG derivative of Siesta developed l Next 12 months – Introduction of Nexus software for network and database management – New product, SynAmpsII – Somté FDA clearance – Siesta upgrade 17
Slide 18: Technology Road Map
Technology Road Map 18
Slide 19: Innovation
Innovation S Series P Series Siesta Somté Nexus 1987 1994 2000 2001 2002 19
Slide 20: Moving Forward
Moving Forward - USA & European distribution issues fixed and working Core - Costs reduced Operations - Integration of both businesses complete - Nexus Release of key new - Synamp II technologies - Stim II - Siesta II Growth platform - Driver fatigue step out - In-depth anesthetic opportunities - Tr
Slide 21: Conclusions
Conclusions 1. Results driven by distribution problems in key markets now resolved. 2. Strong revenue growth in Asia Pacific up 71%. 3. Acquisition and successful integration of Neuroscan business opens up complementary global markets. 4. Business tracking to plan at the end of Q1 and record revenue
Slide 22: Ordinary Business
Ordinary Business l Election of Director. l Mr. Koichiro Koike who retires by rotation offers himself for re-election to the position of Non-Executive Director. 22
Slide 23: Compumedics Limited - End of Business
End of Business Compumedics Limited Annual General Meeting 24 October, 2002 23